Biosimilars: not just a generic

New biosimilars are set to flood into the Australian market over the next several years as patents on biologics expire… but significant concerns remain about switching A steep learning curve is likely for community pharmacists, who to date have had comparatively little involvement in the substitution of biosimilars, as since they began to enter the